Latest Coagulation system Stories
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug.
The Firm is actively investigating potential claims on behalf of patients who allegedly suffered Xarelto internal bleeding, strokes, pulmonary embolism and/or deep vein thrombosis following use
SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/
Phase 1 Clinical Data Highlights Factor IXa as an Excellent Target for Anticoagulation Therapy BASKING RIDGE, N.J., June 23, 2014 /PRNewswire/ -- Regado Biosciences, Inc.
LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy
IMPACT Dx(TM) Combined Function System Will Also Be Available in the European Union SAN DIEGO, June 16, 2014 /PRNewswire/ -- Agena Bioscience, Inc., which recently acquired the Bioscience
LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.